The Malaysia–Singapore ALL 2010 (MS2010) study was one of the first trials focusing on effective chemotherapy in ALL Ph+ pediatric patients with IKZF1 deletions. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.